FDA Approves Polatuzumab Vedotin-piiq + BR for Diffuse Large B-Cell Lymphoma

On June 10, Genentech, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to polatuzumab vedotin-piiq (Polivy^TM) in combination with bendamustine plus rituximab (BR) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies. The FDA's Accelerated Approval Program allows conditional approval of a medicine that fills an unmet medical need for a serious condition.

Read the Genentech press release.

Posted 6/10/2019